Objectives. The aim was to analyse factors influencing the individual colchicine dose in children with FMF, to evaluate the impact of dose adjustment on the clinical course and inflammation and to identify clinical parameters and biomarkers that predict dose increase in the near future.
Introduction
FMF is the most prevalent hereditary periodic fever syndrome, clinically characterized by highly inflammatory febrile attacks, which are associated with signs of serositis, for example, peritonitis, pleuritis and arthritis [1] . Colchicine is the gold standard for prophylaxis of attacks and amyloid deposition [25] . Evidence-based treatment recommendations suggest starting dosages of colchicine according to patient age and subsequent dose escalation in order to control symptoms, (sub)clinical inflammation, or both [68] . This approach implies that in most cases the growing child or the adult in certain cirmcumstances of life, for example, during emotional or physical stress or pregnancy, will experience painful attacks before colchicine dosages will be adjusted. Of note, in the very young child febrile attacks can occur without any other symptoms and thus might be difficult to differentiate from infections [9] . When the individually adequate colchicine dose is found (again), most patients experience a complete control or clear improvement of symptoms and are protected from amyloid deposition.
The quality of life of FMF patients is impaired by the uncertainty of experiencing attacks in the future. This is of special interest in patients with a high disease activity, as reflected by frequent and severe attacks and persistent inflammation, who possibly carry a higher risk of developing amyloidosis in the course of the disease, especially if disease activity is related to high-risk genotypes [10, 11] . Therefore, one target in FMF therapy is the prevention of symptoms by an increase of colchicine dosage, before a series of attacks occurs. Some factors that influence the time of colchicine introduction and dosage in individual patients, for example, the occurrence of the M694V mutation, have been described previously [10, 12, 13] , but no data on risk factors for the development of symptoms during an ongoing colchicine treatment have been described.
In order to identify such potential parameters, we took advantage of the German auto-inflammatory diseases registry, which provides prospective follow-up data from a large number of children and adolescents with FMF as well as serum samples for further analysis of biomarkers. The objective of the study was the identification of factors (e.g. the genotype, different biometrical parameters, different clinical presentations and the degree of inflammation) that might help in adjusting colchicine dosages in an individualized fashion.
Methods

Auto-inflammatory diseases registry
The national auto-inflammatory diseases registry collects clinical data, demographic information and blood samples of children with auto-inflammatory diseases. Details on the registry have previously been published [14, 15] . In January 2016, 1052 patients were registered from 43 participating hospitals.
Inclusion criteria, disease assessment and definitions For this study, inclusion criteria were an age 4 18 years, the clinical diagnosis of FMF according to the TelHashomer criteria, colchicine treatment and at least two documented visits in the registry. Patients in whom another additional auto-inflammatory disease was diagnosed or in whom the documentation of the genotype was unclear were excluded. The national auto-inflammatory disease registry was approved by the institutional ethics committee, and informed consent was obtained from patients and their legal guardians. According to national regulatory bodies, no additional approval or consent was required for this study.
The response to colchicine treatment was calculated by analysing the mean change of CRP concentrations in the 12 months before and after dose increase as well as the change in attack frequency during the same time period. For the analysis of colchicine response, only patients compliant to the medication, with no change of colchicine dosage 12 months before and after the increase and with a follow-up of at least 12 months, were included (therefore, 40 patients were excluded).
Disease severity was assessed by mean of the F-SS-2 (Mor-Score) using the number of attack sites in a single attack and during the disease course, the colchicine dose to achieve remission, the number of pleuritic and erysipelas-like erythema attacks and the age of onset [16] . In the registry, persistent proteinuria and occurrence of amyloidosis were retrieved. In the event of positive answers, centres were asked whether suspected amyloidosis was confirmed or symptoms resolved.
Colchicine resistance was defined as proposed (patient suffers from either more than six typical FMF attacks per year or more than three typical FMF attacks within 46 months despite reaching the maximal tolerable dose according to the EULAR recommendations [7, 8] ).
Laboratory parameters ESR (in millimetres per hour), serum amyloid-A protein (SAA; in nanograms per millilitre) and CRP (in milligrams per litre) were determined by the local institutions. Serum samples were centrifuged within 2 h after acquisition, frozen at À20 C and shipped to Mü nster for analysis of S100 molecules [17] .
Statistical analysis
The cut-off date for this study of the Auto-Inflammatory Diseases-Net registry was in January 2015. Statistical analyses were conducted with the programs IBM SPSS Statistics 22 (IBM Corp, Armonk, NY) and STATA 12.1 (StataCorp LP, College Station, TX).
Data were presented with standard descriptive statistics, including the absolute and relative frequencies for categorical variables and the mean and S.D. for continuously distributed variables. The mean unadjusted and adjusted colchicine doses for a given age were estimated by non-parametric local polynomial regression models for graphical visualization of the data. To assess the impact of colchicine dose increase on CRP concentration and attack frequency, the Wilcoxon signed-rank test was used. In order to identify possible predictors of dose increases, generalized linear mixed models were applied to account for the longitudinal study design. The dependent variables thereby related to the presence or absence of a dose increase in the upcoming months, and the independent variables were the potential predictors. Initially, the potential factors were analysed separately by univariate regression analysis, followed by a multiple regression analysis including all combinations of the factors of interest. The statistical significance level for all tests was P 4 0.05.
Results
Patients
The data of 409 [n = 228 (55.7%) male and n = 181 (44.3%) female] children or adolescents with FMF and colchicine treatment from the auto-inflammatory diseases registry were analysed ( Colchicine was, in general, well tolerated; only 5.4% of the patients showed mild and 0.8% moderate mostly gastrointestinal side-effects according to the World Health Organization toxicity scale (grades 1 and 2, respectively).
Besides colchicine, which was an inclusion criterion for our study, the following concomitant medications were documented: mostly on demand, 81 patients (19.8%) took non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, indomethacin, diclofenac, acetaminophen, aspirin, cyclooxygenase-2 inhibitors) and 19 patients (4.6%) took steroids, whereas continuously, 15 patients (3.7%) took anakinra, 8 patients (2.0%) etanercept, 5 patients (1.2%) methotrexate, 2 patients (0.5%) adalimumab and 1 patient (0.2%) infliximab.
None of the analysed patients demonstrated a positive amyloidosis screening.
Applied colchicine dose according to patient age Previously, it has been recommended that colchicine should be started with an age-adjusted dosage and stepwise increase in the amount of colchicine in order to control symptoms and inflammation [6] . When analysing the whole study population, 0.89 mg colchicine/day was prescribed irrespective of the patients' age and underlying genotype. Figure 1A shows in more detail the colchicine dosages according to age. From the 5th year of life, most patients received 1.0 mg colchicine/day and from the 12th year of life most received 1.5 mg colchicine/day. At the age of 18 years, 32.3% received 2.0 mg colchicine/day and 11.9% >2 mg/day.
Influence of genotype on colchicine dosage
The average colchicine dosages according to the genotype and regardless of the patients' age and anthropometric parameters were calculated. In homozygous M694V mutation carriers, a mean colchicine dose of 1.19 mg/ day was applied. There was no significant difference in comparison to patients carrying compound heterozygous M694V/M680I (1.11 mg) and M694V/V726A (1.16 mg) or homozygous M680I mutations (1.09 mg/day). In contrast, the average colchicine dose was significantly lower in patients with the M694V/E148Q genotype (0.84 mg/day, P < 0.05) or any heterozygous mutation (0.81 mg/day, P < 0.05).
Colchicine dosages were most rapidly increased in patients with homozygous M694V mutations. Within this group, most patients receive at least 1.5 mg/day after 11 years of age (Fig. 1B) . In the compound heterozygous V726A/M694V and M680I/M694V carriers ( Fig. 1D and E), colchicine dose increase was slightly delayed compared with patients with the homozygous M694V mutation. In contrast to the other genotypes, 1 mg/day was the most frequently prescribed colchicine dose in adolescents carrying a heterozygous MEFV mutation (Fig. 1C) .
Influence of anthropometric parameters on colchicine dosage
The analysis of the whole study cohort revealed that the average doses were 0.14 mg colchicine/year of life (median 0.125 mg), 0.036 mg colchicine/kg body weight (median 0.032 mg) and 1.03 mg/m 2 body surface area (median 1.00 mg). The dose of colchicine according to age is high in toddlers, declines in childhood and plateaus in adolescence ( Fig. 2A) . The colchicine dose per kilogram bodyweight continously declines during childhood (Fig. 2B) . The colchicine dose according to the body surface is the most stable variable over time, with values of $1 mg/m 2 throughout childhood and adolescence (Fig. 2C) . But for all parameters-the colchicine dose per years of life (median 0.125 ± 0.39 mg/years of life), body weight (median 0.032 ± 0.02 mg/kg) and body surface area (median 1.00 ± 0.39 mg/m 2 ), respectively-there was a wide range of colchicine doses for all age groups.
Effects of colchicine intake on inflammation and symptoms
Two hundred and thirty-eight of 409 patients had at least one increase of colchicine dosage during follow-up. Compared with the remaining group, more patients carried a homozygous M694V mutation (38.2 vs 11.7%) and Table S1 , available at Rheumatology Online). Within this group, CRP decreased from a mean concentration of 39.3 mg/l to 14.1 mg/l (P 4 0.001). Further dosage increases also led to a subsequent improvement of inflammation as determined by the average CRP concentrations (e.g. after dosage increase to 2 mg colchicine/day, mean CRP declined from 19.8 to 12.6 mg/l and attack frequency was reduced >70% in 22.7% of patients). However, after dosage increases from 1.5 to 2.0 mg colchicine/ day, in 33.3% of patients an increase of inflammation and in 45.5% an increase of attack frequency was detected. The inclusion of patients with low inflammatory activity might mask the effect of colchicine therapy. When analysing only patients with CRP concentrations 5 5 mg/l before dosage increase, an overall better response rate was observed at least in the group receiving low colchicine dosages (supplementary Fig. S1 and supplementary Table S1 , available at Rheumatology Online). Next, the response rates after introduction of colchicine according to the genotype were analysed. Patients with two mutations did not differ significantly in their responses compared with heterozygous patients (Fig. 4A and B, 2 test for group difference in response ( Fig. 4A) : compound heterozygous vs homozygous P = 0.361, compound heterozygous vs heterozygous P = 0.233, homozygous vs heterozygous P = 0.695; and (Fig. 4B) : compound heterozygous vs homozygous P = 0.318, compound heterozygous vs heterozygous P = 0.891 and homozygous vs heterozygous P = 0.951).
The three groups were comparable with respect to age and colchicine dosages (supplementary Tables S2 and  S3, available By applying the recently proposed criteria for colchicine resistance, 15 patients (3.7%) were identified who did not show adequate response to maximally tolerable doses of the drug. Of these 15 patients, 5 were homozygous for M694V, 4 compound heterozygous for M694V/M680I, 3 heterozygous for M694V, 1 compound heterozygous for M694V/V726A, 1 compound heterozygous for V726A/ M680I and 1 homozygous for M680I. The maximal tolerable dosage ranged between 2 and 3 mg colchicine/day.
FIG. 2 Colchicine dose according to different anthropometric parameters and age (in years of life)
The colchicine doses according to the age [in years of life (yol); A], the body weight (in kilograms; B) and the body surface area (in metres squared; C) are plotted against the age (in yol). The line represents the mean applied dose in the respective age group; the scatterplot shows the applied dose per patient. Standardized b corresponds to the standardized regression coefficient. It allows direct comparison of the magnitude of the relative effect of yol on colchicine doses by body weight, body surface and age.
Subsequently, anakinra was started in four patients; in an additional three patients anakinra was introduced temporarily. Furthermore, 11 patients were registered who were already being treated with anakinra before entering the auto-inflammatory diseases registry. In these patients, data on clinical presentation before introduction of anakinra therapy were not available.
Predictors of colchicine dosage increase
In newly treated patients, the severity of disease at diagnosis, assessed by the Mor-Score, decreased the probability of a dosage increase in the first 12 [odds ratio (OR) = 1.60; P = 0.017)] and 24 months (OR = 1.47; P = 0.038). The amount of colchicine initially applied rises with the disease severity [mean colchicine dosage (in milligrams per day)/mean age at start of therapy (in years): mild disease: 0.6/7; moderate: 0.7/5; severe: 0.9/6]. In contrast, other factors, such as sex, age at diagnosis and onset of first symptoms, Pras Score, ethnic origin, skin involvement, genotype (heterozygous, homozygous M694V, M694V/M680I, M694V/V726A, M694V/E148Q, homozygous M680I, V726A/M680I, homozygous E148Q, homozygous V726A, P369S/R408Q, E148Q/P369S), pleural involvement, joint involvement, attack frequency before diagnosis and inflammation parameters, did not show any significant correlation with the probability of a dosage increase in the months after diagnosis (supplementary Table S5 , available at Rheumatology Online).
Next, we analysed whether a single parameter (attack frequency and/or various biomarkers) or combinations of them predicted an upcoming dose increment in patients who were already being treated (Table 2 ). Persistent attacks, as well as elevated CRP, SAA, S100A12 or S100A8/ 9 concentrations, increased (as the sole parameter analysed) the likelihood for a dose increase with a factor of 1.621.94 (KaplanMeier analysis over 24 months; see supplementary Fig. S2 , available at Rheumatology Online). Combining two parameters led to a better predictive value, especially when attack frequency and S100A12 or S100A8/9 were analysed (OR of 3.38 and 3.29). When analysing combinations of three parameters, it became obvious that combining SAA and CRP did not lead to a significant increase in the predictive value. This is also in line with the observation that these markers of inflammation are very well correlated with each other (0.852 and 0.668, respectively; supplementary Table S6 , available at Rheumatology Online). When four or five parameters were increased, the OR for a dosage increase ranged between 4.26 and 4.66. The only exceptions were patients with an increase in four biomarkers but no clinical symptoms (OR = 3.11). When analysing only patients with homozygous M694V mutations even higher associations were observed. In particular, the inclusion of the biomarker S100A12 increased the OR for a dosage increase in the next 12 months up to 7.27 (supplementary Table S7 , available at Rheumatology Online).
FIG. 3 Effect of colchicine dose increase on inflammation and attack frequency
Change between mean CRP 12 months before and 12 months after introduction of colchicine or dose increase (A) and corresponding change of attack frequency (B). Only patients with at least 12 months observation before and after dose increases were analysed. Patients who experienced two dose increases within the observation period were excluded. Numbers of patients in (A)/(B) are as follows: start of colchicine therapy: 213/101; increase from 0.5 to 1.0 mg colchicine/ day: 97/90; increase from 1.0 to 1.5 mg colchicine/day: 81/71; increase from 1.5 to 2.0 mg colchicine/day: 27/22. */**Change of mean CRP concentration/attack frequency before and after introduction of colchicine or dose increase is significant at a level of 4 0.05/40.01 (both sides).
Discussion
The effect of prophylactic colchicine therapy on the prevention of attacks, inflammation and amyloid deposition has been well established in randomized trials [24] and subsequent cohort studies [5, 1822] . Evidence-based guidelines for the use of colchicine in FMF recommend an oral starting dose of 0.5 mg/day or less (<5 years of age), 1.0 mg/day (510 years of age) and 1.5 mg/day (>10 years of age), followed by an increase of colchicine dose up to a maximum of 2.0 mg/day in children and adolescents and 3.0 mg/day in adults in order to control disease and inflammation [6, 7] . Although some individual factors influencing the dose of colchicine in FMF have been previously described, these parameters were not sufficient to allow more personalized treatment recommendations. But ideally, treatment strategies should include as many individual parameters as possible in order to develop individual care programmes.
By using a large cohort of children and adolescents with FMF registered within the national Auto-Inflammatory Diseases-Net, we therefore analysed various factors that influence colchicine dosage in a real-life setting.
Previously, it has been shown that the age of introduction of colchicine [10] and requirement for higher colchicine dosages [12, 13] are associated with mutations at position 694. Our analysis confirms the influence of the genotype on the colchicine dosages administered (heterozygous < compound heterozygous M694V/V726A, and M694V/M680I < homozygous M694V). In patients with homozygous M694V mutations, the colchicine dosages are well correlated with the previously recommended age-dependent doses [68] . But in other genotypes, lower doses were prescribed, especially in patients with heterozygous mutations. Although a large number of visits were registered, further subanalysis of other genotypes or extra correlations, for example, with the degree of subclinical inflammation or persistent clinical symptoms, or both, were hampered by the low patient numbers.
Ideally, the amount of drug needed to control disease activity can be predicted by an easily accessible anthropometric parameter. In our study, young children received higher doses of colchicine according to their body weight compared with older children. A recent analysis demonstrated that steady-state pharmacokinetic parameters are comparable across age groups despite the higher dosages of colchicine on a milligram per kilogram per day basis in the younger age groups [23] . This pharmacokinetical analysis underlines the rationality of applying relatively higher dosages of colchicine in young children. Furthermore, our analysis revealed the best correlation of colchicine intake with the body surface area ($1 mg/m 2 ). This association is remarkably stable, even in a rather high number of very young children. The body surface area is principally recommended to be used as the basis for drug dose calculation in children, because many important physiological factors are correlated with this parameter [24] . But taken together, the wide
FIG. 4 Effect of colchicine introduction on inflammation and attack frequency
The effect of colchicine introduction on inflammation and attack frequency according to the genotype is shown in (A) and (B), respectively. In (A), the change between mean CRP 12 months before and 12 months after colchicine introduction is shown. (B) The change of attack frequency in response to colchicine introduction. Only patients with an observation time of 12 months before and after start of the therapy and registered biomarkers were analysed. Patients who experienced two dose increases within the observation period were excluded. */**Change of mean CRP concentration/attack frequency before and after start of colchicine therapy is significant at a level of 4 0.05/40.01 (both sides).
www.rheumatology.oxfordjournals.org range of prescribed dosages circumvents the use of the body surface area as a single parameter for prediction of the colchicine dosage. One reason (among others discussed in the present study) is the wide range of colchicine bioavailability [25] .
In the present study, we were able to demonstrate that the highest impact of an increase in colchicine on attack frequency and inflammation can be observed when increasing a rather low dose, for example, from 1 to 1.5 mg colchicine/day. In contrast, a substantial number of patients did not benefit from an increase from 1.5 to 2 mg colchicine/day. Given that colchicine therapy is well tolerated even when applied in higher dosages, this still encourages the use of higher doses in individual patients.
One goal of treatment in FMF is the prevention of frequent painful attacks by application of an adequate colchicine dosage. Current treatment regimens recommend a dosage increase in patients with persistent attacks and/or inflammation [6, 8] , thus patients have already experienced an increase in clinical symptoms. Patients presenting with mild disease at diagnosis measured by the Mor-Score were initially treated with lower colchicine dosages and were at higher risk of a dosage increase in the first 24 months. Thus, as soon as the diagnosis of FMF is established, appropriate colchicine dosages should be applied irrespectively of the disease severity.
In line with previous studies that demonstrated the high sensitivity of S100 molecules in the detection of inflammation in FMF [17, 26, 27] , our data prove the clinical relevance of increased S100 serum concentrations in the prediction of a dosage increase in FMF patients already being treated. Furthermore, these data suggest that SAA and CRP are correlated very well with each other; thus, a combined analysis of these parameters does not increase the accuracy of prediction of a dosage increase.
Another reason for prophylactic colchicine application is the prevention of amyloid deposition. Early disease onset [28] , the M694V genotype [29, 30] , a positive family history, male sex [31] and environmental factors [32] are predictors for the occurrence of amyloidosis. In this group of patients, it seems to be especially important to limit periods of short-term high and long-term subclinical inflammation by appropriate adjustment of the colchicine dosage. Thus, in this group the predictors for an upcoming dosage increase should be evaluated carefully. But given that a recently performed meta-analysis could not identify any inflammation marker that is superior over the others in order to predict long-term outcome, it is not possible to define a limit of acceptable subclinial inflammation [7] . In summary, this work comprehensively analysed factors influencing colchicine therapy in children and adolescents with FMF and demonstrated the usefulness of S100 molecules as biomarkers for dosage increases of colchicine. Although colchicine dosage will still be guided mainly by the occurrence of clinical symptoms and inflammation, the risk factors described will help to adapt the treatment intensity individually in order to prevent disease exacerbation in the upcoming months and years.
